Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) EBIT per Share : $-0.57 (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Coeptis Therapeutics Holdings EBIT per Share?

Coeptis Therapeutics Holdings's EBIT per Share for the three months ended in Mar. 2024 was $-0.08. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.57.

During the past 3 years, the average EBIT per Share Growth Rate was -36.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Coeptis Therapeutics Holdings's EBIT per Share or its related term are showing as below:

COEP' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -36.7 Med: -36.7 Max: -36.7
Current: -36.7

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Coeptis Therapeutics Holdings was -36.70% per year. The lowest was -36.70% per year. And the median was -36.70% per year.

COEP's 3-Year EBIT Growth Rate is ranked worse than
85.74% of 1304 companies
in the Biotechnology industry
Industry Median: 3.6 vs COEP: -36.70

Coeptis Therapeutics Holdings's EBIT for the three months ended in Mar. 2024 was $-2.80 Mil.

Coeptis Therapeutics Holdings EBIT per Share Historical Data

The historical data trend for Coeptis Therapeutics Holdings's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coeptis Therapeutics Holdings EBIT per Share Chart

Coeptis Therapeutics Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.44

-0.65

-2.61

-0.82

Coeptis Therapeutics Holdings Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial									-0.40	-0.15	-0.24	-0.11	-0.08

Coeptis Therapeutics Holdings EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Coeptis Therapeutics Holdings's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-21.159	/	25.690
=	-0.82

Coeptis Therapeutics Holdings's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.801	/	35.545
=	-0.08

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.57

Coeptis Therapeutics Holdings (NAS:COEP) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Coeptis Therapeutics Holdings EBIT per Share Related Terms

Thank you for viewing the detailed overview of Coeptis Therapeutics Holdings's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coeptis Therapeutics Holdings Inc (NAS:COEP) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

105 Bradford Road, Suite 420, Wexford, PA, USA, 15090

Website

https://www.coeptistx.com

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio comprises multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Executives

Tara Desilva	director	105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
David Mehalick	director, 10 percent owner, officer: CEO and President	5000 TRESSDALE DRIVE, GIBSONIA PA 15044
Christopher P. Cochran	director	105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
Gene Salkind	director	1165 WRACK ROAD, MEADOWBROOK PA 19046
Daniel Alexander Yerace	director, officer: VP of Operations	402 SCHOMBURG COURT, CRANBERRY TOWNSHIP PA 16066
Chris Calise	director, 10 percent owner, officer: Chief Financial Officer	801 S. POINTE DRIVE SUITE TH-1, MIAMI BEACH FL 33139
Philippe Deschamps	director	105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Christine Elise Sheehy	officer: CFO and Secretary	206 TAMARACK DRIVE, MARS PA 16046
Harraden Circle Investments, Llc	10 percent owner	299 PARK AVE, 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Lp	10 percent owner	299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Llc	10 percent owner	299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Fortmiller Frederick Vincent Jr.	10 percent owner	151 LULL ROAD, NEW BOSTON NH 03070
Harraden Circle Investors, Lp	10 percent owner	299 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10171
Plc Barclays	10 percent owner	1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Paul J Glazer	10 percent owner	250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019